Atossa Therapeutics (ATOS) Q4 2024 earnings summary

Executive summary

• (Z)-endoxifen advanced as a next-generation anti-estrogen therapy, targeting key gaps in breast cancer treatment, especially metastatic disease, with a focus on expedited approval and streamlined regulatory pathway.

• Clinical data from multiple Phase I and II studies show robust activity, improved tolerability, significant tumor suppression, and superior efficacy and safety in metastatic, neoadjuvant, and prevention trials.

• Ongoing engagement with FDA and key opinion leaders to finalize trial design and regulatory pathway for (Z)-endoxifen in metastatic breast cancer.

• Ended 2024 with $71.1 million in cash and cash equivalents and no debt, maintaining a strong liquidity position.

• High unmet need persists in endocrine therapy for breast cancer, with significant patient discontinuation and resistance rates.

Financial highlights

• Total operating expenses for 2024 were $27.6 million, down from $31.4 million in 2023, reflecting disciplined R&D and G&A spending.

• Net loss for 2024 was $25.5 million ($0.20 per share), improved from $30.1 million ($0.24 per share) in 2023.

• R&D expenses decreased by $3.2 million year-over-year, mainly due to lower clinical and preclinical spending and reduced stock-based compensation.

• Interest income was $4.1 million, slightly down from $4.3 million in the prior year.

• Ended 2024 with $71.1 million in cash and cash equivalents, with no outstanding debt.

Outlook and guidance

• Plans to consult with key opinion leaders and the FDA over the next 4–6 months to define clinical trial parameters for (Z)-endoxifen in metastatic breast cancer.

• Ongoing and future clinical trials include neoadjuvant and prevention settings for (Z)-endoxifen, with key data expected in late 2024 and early 2026.

• Focused on U.S. FDA approval in 2025, with potential expansion to other markets in early 2026.

• (Z)-endoxifen is positioned for expansion into earlier-stage disease settings and as a preferred combination partner.

• Continued commitment to advancing (Z)-endoxifen into earlier disease settings and combination therapies.